Marinus Pharmaceuticals, Inc.
http://marinuspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Marinus Pharmaceuticals, Inc.
Finance Watch: Verona Accesses Up To $650m As Ensifentrine Approval Deadline Nears
Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
EU’s Innovative Drug Approval Tally Shows Sharp Decline
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
Marinus On Track To Be Leader In Rare Epilepsy Market, Says CEO
CEO Scott Braunstein, who took leadership of Marinus in 2019 following clinical trial setbacks, believes the company is on a route to success with its ganaxolone program, targeting chronic use and hospital markets.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice